We present our initial experience of applying HP 13C pyruvate MRI in patients with renal tumors. Distinct tumor metabolic pattern and heterogeneity can be observed on HP 13C pyruvate MRI. Our data from subjects with two injections also suggests that the metabolite measurements are reproducible. This initial experience paves the way for this metabolic imaging technique to be applied for differentiating between benign renal tumors, low grade RCCs and high grade RCCs.
This abstract and the presentation materials are available to members only; a login is required.